Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia

Driggin, 2020, Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic, J Am Coll Cardiol, 75, 2352, 10.1016/j.jacc.2020.03.031

Tada, 2015, Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography, Am J Cardiol, 115, 724, 10.1016/j.amjcard.2014.12.034

Sorensen, 1994, Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level, J Clin Invest, 93, 50, 10.1172/JCI116983

Charakida, 2009, Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia, Atherosclerosis, 204, 532, 10.1016/j.atherosclerosis.2008.09.025

Vuorio, 2020, Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities, J Intern Med, 287, 2, 10.1111/joim.12981

Mehra, 2020, Cardiovascular disease, drug therapy, and mortality in Covid-19, N Engl J Med, 10.1056/NEJMc2021225

Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5

Schol-Gelok, 2018, Clinical effects of antiplatelet drugs and statins on D-dimer levels, Eur J Clin Invest, 48, e12944, 10.1111/eci.12944

Raal, 2015, PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hyperc- holesterolaemia (RUTHERFORD-2): a randomised, double- blind, placebo-controlled trial, Lancet, 385, 331, 10.1016/S0140-6736(14)61399-4

Kastelein, 2015, ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, Eur Heart J, 36, 2996

Undas, 2005, Statins and Blood Coagulation, Arterioscler Thromb Vasc Biol, 25, 287, 10.1161/01.ATV.0000151647.14923.ec